Terumo and Propofol Injectable, page-118

USPTO has published Phosphagenics’ application for a Pharmaceutical Formulation patent which is intended to protect the use of TPM in a broad range of injectable formulations (Pub. No: 20190015329, Pub. Date: 17/01/19). This patent, along with a joint Phosphagenics-Terumo patent specifically for TPM/Propofol, was referred to by the company in a November 2017 update.

The TPM formulation is described as suitable for topical, enteral or parenteral administration, but is considered particularly suitable as an injectable formulation.

https://www.uspto.gov/